IP Library Granted Patent US 12712060
Granted Patent B2
US 12712060 · App. 18/843,201 · Granted Aug 18, 2026

Multi-modal crypto/bio-human-machine interface

Inventors: Sam Emaminejad (Los Angeles, CA); Shuyu Lin (Los Angeles, CA); Jialun Zhu (Los Angeles, CA); Wenzhuo Yu (Los Angeles, CA)
Assignee: The Regents of the University of California
G16H20/13G06F3/011G06F21/32G16H50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12712060
App. No.
18/843,201
Granted
Aug 18, 2026
Kind
B2
Abstract

The present embodiments relate to a multimodal cryptographic bio-human machine interface (“CB-HMI”), which seamlessly translates the user's touch-based entries into encrypted biochemical, biophysical, and biometric indices. The CB-HMI features thin hydrogel-coated chemical sensors and inference algorithms to non-invasively and inconspicuously acquire biochemical indices such as circulating molecules that partition onto the skin (here, ethanol and acetaminophen). Additionally, the CB-HMI hosts physical sensors and associated algorithms to simultaneously acquire the user's heart rate, blood oxygen level, and fingerprint minutiae pattern. Additional or alternative embodiments include a touch-based non-invasive monitoring solution for lithium pharmacotherapy management. The system is constructed based on a thin organohydrogel-coated lithium ion-selective electrode (TOH-ISE), where the TOH coating was engineered to render stabilized conditions for sensing. In particular, by adopting a water glycerol bi-solvent matrix, the gel features antidehydration property, rendering a controlled micro-environment for the ISE to condition and minimized the signal drift.

Claims (21)

1 . A device comprising:

a multimodal cryptographic bio-human machine interface (“CB-HMI”) configured to translate a user's touch-based entries and/or other biomarkers into encrypted biometric indices, the CB-HMI including a service activator that receives the encrypted biometric indices and determines whether to activate a service for the user based on an analysis of biomarkers and identity information included in the encrypted biometric indices.

2 . The device of claim 1 , wherein the CB-HMI further includes thin hydrogel-coated chemical sensors and inference algorithms to non-invasively acquire biomarkers and/or biochemical indices such as circulating molecules that partition onto the skin.

3 . The device of claim 2 , wherein the circulating molecules comprise one or both of ethanol and acetaminophen.

4 . The device of claim 1 , wherein the CB-HMI further includes physical sensors and associated algorithms to simultaneously acquire one or more of the user's heart rate, blood oxygen level, blood pressure, respiratory rate, and fingerprint minutiae pattern.

5 . The device of claim 1 , wherein the CB-HMI is further configured to acquire physiologically-relevant readouts of target bio-indices and to biometrically encrypt and decrypt these bio-indices in-situ using a fingerprint sensor.

6 . The device of claim 1 , wherein the service is associated with driving safety and medication use.

7 . The device of claim 6 wherein the service activator is included in a vehicle activation system.

8 . The device of claim 6 wherein the service activator is included in a medication dispensing system.

9 . The device of claim 1 , wherein the CB-HMI includes a gel-coated lithium sensing interface to collect and analyze partitioned lithium ions on fingertips in-situ.

10 . The device of claim 1 , wherein the biomarkers included in the analysis include one or more of the user's heart rate, blood oxygen level, blood pressure and respiratory rate.

11 . The device of claim 1 , wherein the biomarkers included in the analysis include a detected level of ethanol in the user's fingertip.

12 . The device of claim 11 , wherein the detected level of ethanol is determined from an analysis of the user's sweat.

13 . The device of claim 1 , wherein the biomarkers included in the analysis include a detected level of acetaminophen in the user's fingertip.

14 . The device of claim 13 , wherein the detected level of acetaminophen is determined from an analysis of the user's sweat.

15 . A device comprising:

a touch-based non-invasive lithium monitoring solution, including a gel-coated lithium sensing interface to collect and analyze partitioned lithium ions on fingertips in-situ.

16 . The device of claim 15 , wherein the interface comprises a thin organohydrogel-coated lithium ion-selective electrode (TOH-ISE), wherein the TOH simultaneously addresses stability challenges associated with the sensing interface.

17 . The device of claim 16 , wherein the TOH comprises a water-glycerol bi-solvent matrix, having an anti-dehydration property.

18 . The device of claim 16 , wherein when coupled with a lithium ISE, the TOH coating serves as a controlled micro-environment to condition the ISE in-situ.

19 . The device of claim 16 , wherein the TOH-ISE includes a ISE-specific signal interpretation framework that is capable of extracting the lithium flux information from touch-based readouts.